Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.66 USD
Change Today +0.16 / 4.57%
Volume 5.0K
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

volitionrx ltd (VNRX) Snapshot

Open
$3.70
Previous Close
$3.50
Day High
$3.72
Day Low
$3.55
52 Week High
09/22/14 - $9.28
52 Week Low
06/9/14 - $1.30
Market Cap
65.6M
Average Volume 10 Days
17.8K
EPS TTM
--
Shares Outstanding
17.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VOLITIONRX LTD (VNRX)

Related News

No related news articles were found.

volitionrx ltd (VNRX) Related Businessweek News

No Related Businessweek News Found

volitionrx ltd (VNRX) Details

VolitionRX Limited, a clinical-stage life sciences company, focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is involved in the development of 20 epigenetic NuQ blood assays based on its Nucleosomics biomarker platform. It develops two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer. The company also develops nine blood assays in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones that are proteins for packaging and ordering DNA into nucleosomes; five blood assays in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts; and a NuQ-T assay to detect cancer by detecting total blood nucleosome levels, as well as offers research kits. In addition, it develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help appropriate therapy; NuQ tests for non-cancer conditions; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.

10 Employees
Last Reported Date: 03/18/15

volitionrx ltd (VNRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Chief Financial Officer and Treasurer
Total Annual Compensation: --
Chief Medical Officer and Head of US Operatio...
Total Annual Compensation: --
Secretary
Total Annual Compensation: --
Chief Scientific Officer of Belgian Volition ...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

volitionrx ltd (VNRX) Key Developments

VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2015

VolitionRx Limited reported earnings results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, the company reported a net loss of $2 million, or $0.12 per share. This compares to a net loss of $2.2 million, or $0.18 per share in the first quarter of 2014.

VolitionRx Accelerates Clinical Trial with University Hospital Bonn, Germany Evaluating NuQ® Assays in Most Prevalent Cancers

VolitionRx Limited announced that it has accelerated its large independent prospective study evaluating its proprietary Nucleosomics® platform at University Hospital Bonn in Germany. The study initially included 4,000 patient blood samples across 20 of the most prevalent cancer types, and has now been expanded to include approximately 4,200-patient blood samples across 27 of the most prevalent cancers, including: two types of respiratory cancer, seven types of gastrointestinal cancer, four gynecological cancers, four urinary cancers, four types of hematological cancer, plus melanoma, sarcoma and cancers of the thyroid and brain; as well as control patients with 24 other conditions and healthy individuals. In total, the cancer types being analyzed represent over 95% of the incidence of cancer.

VolitionRX Ltd, Q1 2015 Earnings Call, May 12, 2015

VolitionRX Ltd, Q1 2015 Earnings Call, May 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNRX:US $3.66 USD +0.16

VNRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNRX.
View Industry Companies
 

Industry Analysis

VNRX

Industry Average

Valuation VNRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4,073.7x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3,692.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VOLITIONRX LTD, please visit www.volitionrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.